Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lymphoma, T-Cell, Peripheral 6Lymphoma, T-Cell 5Recurrence 4Lymphoma 4Lymphoma, Non-Hodgkin 3Lymphoma, Large-Cell, Anaplastic 3Immunoblastic Lymphadenopathy 3Neoplasm Metastasis 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Hodgkin Disease 2Esophageal Squamous Cell Carcinoma 2Adenocarcinoma Of Esophagus 2Waldenstrom Macroglobulinemia 1Urinary Bladder Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Subcutaneous panniculitis-like T-cell lymphoma 1Stomach Neoplasms 1Smoking 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Mycosis Fungoides 1Lymphoproliferative Disorders 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Lung Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1

Interventions

Tobacco Use Cessation Devices 2zileuton 1olaparib 1Vitamin B 12 1Varenicline 1Radiotherapy 1Patient Navigation 1Nicotine Replacement Therapy 1Folic Acid 1Erlotinib Hydrochloride 1Cycloserine 1Cetuximab 1Celecoxib 1Budesonide 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Smoking × 10-propargyl-10-deazaaminopterin × Clear all
NCT00606502 2021-03-05

Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment

Spectrum Pharmaceuticals, Inc

Phase 2 Completed
201 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Smoking

Data powered by HemOnc (CC BY 4.0) Colophon âš¡